IDNA Genomics Public Ltd (CYS:IDNA)

IDNA Genomics Public Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Revenue	0.51	0.48	0.49
Revenue Growth (YoY)	-	-3.01%	-
Cost of Revenue	0.5	0.35	0.17
Gross Profit	0.01	0.13	0.32
Selling, General & Admin	1.75	1.67	1.54
Other Operating Expenses	-0.07	-0.07	-0.01
Operating Expenses	1.68	1.61	1.53
Operating Income	-1.67	-1.48	-1.2
Interest Expense	-0.19	-0.15	-0.13
Other Non Operating Income (Expenses)	0.01	-0	-0
EBT Excluding Unusual Items	-1.85	-1.63	-1.34
Impairment of Goodwill	-1.34	-1.34	-
Pretax Income	-3.19	-2.97	-1.34
Income Tax Expense	0.01	0.01	0.01
Earnings From Continuing Operations	-3.2	-2.97	-1.34
Minority Interest in Earnings	0.69	0.45	-
Net Income	-2.51	-2.52	-1.34
Net Income to Common	-2.51	-2.52	-1.34
Shares Outstanding (Basic)	3	3	3
Shares Outstanding (Diluted)	3	3	3
EPS (Basic)	-0.91	-0.91	-0.49
EPS (Diluted)	-0.91	-0.91	-0.49
Free Cash Flow	-2.77	-2.53	-0.01
Free Cash Flow Per Share	-1.00	-0.92	-0.01
Gross Margin	1.99%	27.22%	65.56%
Operating Margin	-325.63%	-309.19%	-244.23%
Profit Margin	-489.80%	-527.75%	-272.77%
Free Cash Flow Margin	-540.44%	-528.51%	-2.62%
EBITDA	-1.64	-1.31	-1.12
EBITDA Margin	-	-274.54%	-227.85%
D&A For EBITDA	0.03	0.17	0.08
EBIT	-1.67	-1.48	-1.2
EBIT Margin	-	-	-244.23%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.